Arix Bioscience Plc – Artios completes £65m Series B investment round

  • Arix interest increased to £15.3 million ($19.7 million1), becoming largest shareholder in Artios.
  • Supporting proven management team in accelerating development of next generation DNA Damage Response (DDR) pipeline

Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today announces that its Group Business Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, has completed an oversubscribed £65 million ($84 million1) Series B financing (the “Financing”) following strong interest from investors.

To continue reading the press release please click here

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...